|
|
 |
| Ova Antigen Delivery Reagent |
|
| Overview |
The Ova Antigen Delivery Reagent has been developed for efficient in vitro targeting of ovalbumin to antigen-presenting cells (APCs), for example, DCs. The reagent consists of a monoclonal anti-biotin antibody conjugated to ovalbumin and FITC. In combination with an appropriate biotinylated anti-receptor antibody, any desired antigen uptake receptor can be targeted.
The Antigen Delivery Module Set comprises all the reagents that are required for the isolation of DCs, antigen delivery, and subsequent analysis of antigen presentation. |
| Details |
Background information
Antigen targeting to APCs via specific receptors has been used to induce effective antigen-specific T cell responses.1–5 This allows the functional characterization of new receptors on APCs for comparison with well-characterized ones, such as CD205 (DEC205) or DCIR2 (33D1).
Downstream applications
The Ova Antigen Delivery Reagent features efficient and straightforward targeting of ovalbumin to APCs and is a powerful tool for:
- analysis of antigen uptake, processing, and intracellular trafficking,
- analysis of cross-presentation,
- development of antigen delivery protocols for DC vaccination.
|
| |
| Figure 1 |
| Proliferation of CD4+ T cells induced by antigen-presenting DCs was detected by CFSE labeling. CD4+ T cells from DO11.10 mice were cultured with DCs that were previously isolated using CD11c MicroBeads. Ovalbumin was targeted to DCs via Dectin-1, CD205 (DEC205), or DCIR2 (33D1), using biotinylated antibodies against the respective antigen uptake receptors in combination with the Ova Antigen Delivery Reagent. Cells were cultured in the presence of Pam3CysSK4 that induces DC maturation via toll-like receptors. In the absence of Ova Antigen Delivery Reagent no T cell proliferation was detected. |
| Dectin-1 |
 |
| CD205 (DEC205) |
 |
| DCIR2 (33D1) |
 |
| Control |
 |
|
|
|
|
| Favorites / Prices |
Request prices or add products to your favorite list.
|
| Details |
|
| References |
| 1. Bonifaz et al. (2002) J. Exp. Med. 196: 1627–1638. |
| 2. Dudziak et al. (2007) Science 315: 107–111. |
| 3. Mouriès et al. (2008) Blood 112: 3713–3722. |
| 4. Caminschi et al. (2008) Blood 112: 3264–3273. |
| 5. Sancho et al. (2008) J. Clin. Invest. 118: 2098–2110. |
|
|
|
© 1999 - 2012 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|
